Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Evelo Biosciences Inc (EVLO) COM USD0.001

Sell:$7.17 Buy:$7.18 Change: $0.02 (0.28%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: $0.02 (0.28%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: $0.02 (0.28%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Evelo Biosciences, Inc. is engaged in developing therapies designed to act on gut-body network. The Company develops monoclonal microbes that are orally-delivered compositions of specific strains of naturally occurring microbes derived from a single clone. Its principal product candidates include EDP1066, EDP1815, and EDP1503 that are in the pre-clinical development stage. EDP1066 and EDP1815 are monoclonal microbial product candidates that are developed to treat inflammatory diseases that include psoriasis, atopic dermatitis, rheumatoid arthritis, and ulcerative colitis. EDP1503 is the Company's product candidate developed under oncology portfolio to treat diseases, such as colorectal cancer, renal cell carcinoma, and melanoma among others.

Contact details

620 Memorial Dr Ste 200
United States
+1 (617) 8708281

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$445.34 million
Shares in issue:
53.40 million
United States
US dollar

Key personnel

  • David Epstein
    Chairman of the Board
  • Balkrishan Gill
    President, Chief Executive Officer, Director
  • Luca Scavo
    Chief Financial Officer, Senior Vice President, Treasurer
  • Mark Bodmer
    Chief Scientific Officer, President of Research and Development
  • Daniel Char
    General Counsel, Secretary
  • Duncan McHale
    Chief Medical Officer
  • Jonathan Zung
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.